Natco Pharma, Lupin alliance secures U.S. FDA nod for generic breast cancer drug
The U.S. Food and Drug Administration has approved Natco Pharma’s abbreviated new drug application (ANDA) for cancer drug Eribulin Mesylate Injection. File | Photo Credit: Getty Images The U.S. Food and Drug Administration (U.S FDA) has approved Natco Pharma’s abbreviated new drug application (ANDA) for cancer drug Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) single-dose…
Read More “Natco Pharma, Lupin alliance secures U.S. FDA nod for generic breast cancer drug” »